💲 Tirzepatide: A Cost-Effective Path to Obesity Management
This academic article presents a cost-effectiveness analysis of tirzepatide, a medication for managing overweight and obesity, comparing it against lifestyle modification (LSM) alone. Researchers used a simulation model to project lifetime health outcomes and costs for patients, focusing on complications like cardiovascular events, type 2 diabetes, cancer, osteoarthritis, and sleep apnea. The study concluded that all tested doses of tirzepatide were cost-effective alternatives to LSM, falling […]
Oral Semaglutide Offers Kidney Benefits in T2D
In a real-world setting, the administration of oral semaglutide leads to a significant reduction in the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and albuminuria. Medscape News UK
Targeted in vivo gene integration of a secretion-enabled GLP-1 receptor agonist reverses diet-induced non-genetic obesity and pre-diabetes – Communications Medicine
submitted by /u/SpiritGaming28 [link] [comments]
STAT+: Senators reveal how much Lilly, Pfizer paid telehealth companies
Over the last nine months, four senators led by Sen. Dick Durbin (D-Ill.) have conducted an inquiry into the growing partnerships between direct-to-consumer telehealth companies and pharmaceutical manufacturers. In the last two years, both Pfizer and Eli Lilly launched websites that, among other things, connect patients with a telehealth provider for conditions their medications treat. […]
Could weight loss drugs like Ozempic help combat addiction?
GLP-1 drugs like Ozempic and Zepbound are some of the biggest blockbusters in pharmaceutical history. The overdose epidemic is one of the biggest public health crises in the U.S. Read the rest…
59% of GLP-1 Users Say the Drug Changed Their Dating Lives
DatingAdvice.com GLP-1s double as not only a weight loss drug but also a dating confidence booster. Fifty-nine percent of surveyed GLP-1 users report changes in their dating lives…
Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
Abstract Aims Sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have cardio-kidney-metabolic benefit. This study aimed to understand the prevalence of prescription of SGLT2 inhibitors and GLP1-RA among patients with T2DM with and without chronic kidney disease (CKD) in Australian primary care. Materials and Methods We conducted a retrospective, cohort study […]
DELAYING STOMACH EMPTYING WILL DO THAT: GLP-1 drugs increase risk of acid reflux, GERD, study finds
DELAYING STOMACH EMPTYING WILL DO THAT: GLP-1 drugs increase risk of acid reflux, GERD, study finds.
[Comment] Beyond a singular focus on GLP-1: why we need a new nomenclature now
The development of glucagon-like peptide-1 (GLP-1)-based therapies for type 2 diabetes and obesity illustrates a remarkable evolution in scientific understanding and therapeutic innovation.1 As the field moves rapidly beyond a singular focus on GLP-1 receptor agonism, the language surrounding these new and emerging therapies should also evolve, capturing the growing complexity and ambition behind these […]
“Ozempic Butt” Is a Real Side Effect of the Drug – Here’s What It Means
Image Source: Getty / Luis Alvarez By now, you’ve probably heard all about Ozempic. The popular drug is a brand name for semaglutide, which is primarily used to help people with type 2 diabetes better manage their symptoms. However, over the last few months, conversations around the injection have shifted, thanks to people starting to […]